Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:16:38.072Z.
Calculation as of: 2026-10-06T16:16:38.072Z.
Quote observation: 2026-10-06T16:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$5.13B
PS Ratio
N/A
TTM Avg
12.01
3Y Avg
39.75
5Y Avg
43.00
Market Cap
$5.21B
PS Ratio
389.12
TTM Avg
715.74
3Y Avg
272.12
5Y Avg
564.99
Market Cap
$4.85B
PS Ratio
2547.20
TTM Avg
1806.21
3Y Avg
686.61
5Y Avg
531.46
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Erasca, Inc. (ERAS) | $5.09B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.09B | 3.23 | 3.11 | 3.69 | 3.59 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.13B | N/A | 12.01 | 39.75 | 43.00 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | 389.12 | 715.74 | 272.12 | 564.99 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.23B | N/A | 339.12 | 118.01 | 104.25 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.89B | 7.91 | 9.96 | 8.15 | 13.53 |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.85B | 2547.20 | 1806.21 | 686.61 | 531.46 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.84B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.32B | 8.12 | 10.47 | 14.75 | 18.94 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.35B | 5.30 | 4.89 | 3.61 | 4.09 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
